Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
Open Access
- 3 March 2023
- journal article
- letter
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (4) , 419-422
Abstract
No abstract availableKeywords
Funding Information
- Deutsches Zentrum für Infektionsforschung (80018019238)
- EC | European Regional Development Fund (Defeat Corona, ZW7-8515131)
- Bundesministerium für Forschung, Technologie und Raumfahrt (01KI20328A, 01KX2021)
- Niedersächsische Ministerium für Wissenschaft und Kultur (14-76103-184, COFONI Network, including projects 7FF22, 6FF22, 10FF22)
- European Commission (project UNDINE)
- Deutsche Forschungsgemeinschaft (PO 716/11-1, PO 716/14-1)
This publication has 11 references indexed in Scilit:
- Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent VaccineNew England Journal of Medicine, 2023
- Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineageThe Lancet Infectious Diseases, 2023
- Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolutionNature, 2022
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisationThe Lancet Infectious Diseases, 2022
- Omicron sublineage BQ.1.1 resistance to monoclonal antibodiesThe Lancet Infectious Diseases, 2022
- Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domainsPLOS Pathogens, 2022
- Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 VaccinebioRxiv, 2022
- The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineagesThe Lancet Infectious Diseases, 2022
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesJournal of Experimental Medicine, 2020